Levopalm-M Tablet is a combination medication containing Levocetirizine 5mg and Montelukast 10mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea associated with allergic responses. Montelukast, a leukotriene receptor antagonist, blocks the cysteinyl leukotriene D4 receptor in the airways, leading to decreased bronchoconstriction, inflammation, and mucus production. The synergistic action of these agents provides comprehensive relief from both immediate and late-phase allergic reactions. Levopalm-M is particularly useful in patients requiring control of nasal and ocular symptoms along with prevention of bronchospasm triggered by allergens or exercise. The recommended dosage is one tablet once daily, preferably in the evening, to optimize therapeutic outcomes. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision in pregnant or lactating women. Common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. Levopalm-M offers an effective and well-tolerated option for the integrated management of allergic disorders.